Validation of a scoring system to evaluate the risk of rapid growth of intracranial meningiomas in neurofibromatosis type 2 patients

View More View Less
  • 1 Department of Neurosurgery and
  • 3 Neurosurgical Intensive Care, Pitié-Salpêtrière Hospital, Assistance Publique-Hôpitaux de Paris;
  • 2 Sorbonne Universités, Paris;
  • 4 Department of Neurosurgery, Beaujon Hospital, Assistance Publique-Hôpitaux de Paris; and
  • 5 Department of Genetics and Molecular Biology, Cochin Hospital, Assistance Publique-Hôpitaux de Paris, France
Restricted access

Purchase Now

USD  $45.00

JNS + Pediatrics - 1 year subscription bundle (Individuals Only)

USD  $505.00

JNS + Pediatrics + Spine - 1 year subscription bundle (Individuals Only)

USD  $600.00
Print or Print + Online

OBJECTIVE

Intracranial meningiomas occur in about half of neurofibromatosis type 2 (NF2) patients and are very frequently multiple. Thus, estimating individual meningiomas’ growth rates is of great interest to tailor therapeutic interventions. The Asan Intracranial Meningioma Scoring System (AIMSS) has recently been published to estimate the risk of tumor growth in sporadic meningiomas. The current study aimed to determine predictors of rapid meningioma growth in NF2 patients and to evaluate the AIMSS score in a specific NF2 cohort.

METHODS

The authors performed a retrospective analysis of 92 NF2 patients with 358 measured intracranial meningiomas that had been observed prospectively between 2012 and 2018. Tumor volumes were measured at diagnosis and at each follow-up visit. The growth rates were determined and evaluated with respect to the clinicoradiological parameters. Predictors of rapid tumor growth (defined as growth ≥ 2 cm3/yr) were analyzed using univariate followed by multivariate logistic regression to build a dedicated predicting model. Receiver operating characteristic (ROC) curves to predict the risk of rapid tumor growth with the AIMSS versus the authors’ multivariate model were compared.

RESULTS

Sixty tumors (16.76%) showed rapid growth. After multivariate analysis, a larger tumor volume at diagnosis (p < 0.0001), presence of peritumoral edema (p = 0.022), absence of calcifications (p < 0.0001), and hyperintense or isointense signal on T2-weighted MRI (p < 0.005) were statistically significantly associated with rapid tumor growth. It is particularly notable that the genetic severity score did not seem to influence the growth rate of NF2 meningiomas. In comparison with the AIMSS, the authors’ multivariate model’s prediction did not show a statistically significant difference (area under the curve [AUC] 0.82 [95% CI 0.76–0.88] for the AIMSS vs AUC 0.86 [95% CI 0.81–0.91] for the authors’ model, p = 0.1).

CONCLUSIONS

The AIMSS score is valid in the authors’ cohort of NF2-related meningiomas. It adequately predicted risk of rapid meningioma growth and could aid in decision-making in NF2 patients.

ABBREVIATIONS AIMSS = Asan Intracranial Meningioma Scoring System; AUC = area under the curve; GKRS = Gamma Knife radiosurgery; NF2 = neurofibromatosis type 2; ROC = receiver operating characteristic; T2W = T2-weighted.

Supplementary Materials

    • Supplemental Figs 1 through 3 (PDF 732 KB)

JNS + Pediatrics - 1 year subscription bundle (Individuals Only)

USD  $505.00

JNS + Pediatrics + Spine - 1 year subscription bundle (Individuals Only)

USD  $600.00

Contributor Notes

Correspondence Michel Kalamarides: Hôpital de la Pitié Salpêtrière, Paris, France. michel.kalamarides@aphp.fr.

INCLUDE WHEN CITING Published online May 22, 2020; DOI: 10.3171/2020.3.JNS192382.

Disclosures The authors report no conflict of interest concerning the materials or methods used in this study or the findings specified in this paper.

  • 1

    Evans DG, Howard E, Giblin C, Birth incidence and prevalence of tumor-prone syndromes: estimates from a UK family genetic register service. Am J Med Genet A. 2010;152A(2):327332.

    • Search Google Scholar
    • Export Citation
  • 2

    Evans DG, Sainio M, Baser ME. Neurofibromatosis type 2. J Med Genet. 2000;37(12):897904.

  • 3

    Asthagiri AR, Parry DM, Butman JA, Neurofibromatosis type 2. Lancet. 2009;373(9679):19741986.

  • 4

    Aboukais R, Zairi F, Baroncini M, Intracranial meningiomas and neurofibromatosis type 2. Acta Neurochir (Wien). 2013;155(6):9971001.

  • 5

    Goutagny S, Bah AB, Henin D, Long-term follow-up of 287 meningiomas in neurofibromatosis type 2 patients: clinical, radiological, and molecular features. Neuro Oncol. 2012;14(8):10901096.

    • Search Google Scholar
    • Export Citation
  • 6

    Baser ME, Friedman JM, Aeschliman D, Predictors of the risk of mortality in neurofibromatosis 2. Am J Hum Genet. 2002;71(4):715723.

  • 7

    Dirks MS, Butman JA, Kim HJ, Long-term natural history of neurofibromatosis Type 2-associated intracranial tumors. J Neurosurg. 2012;117(1):109117.

    • Search Google Scholar
    • Export Citation
  • 8

    Evers S, Verbaan D, Sanchez E, Peerdeman S. 3D Volumetric measurement of neurofibromatosis type 2-associated meningiomas: association between tumor location and growth rate. World Neurosurg. 2015;84(4):10621069.

    • Search Google Scholar
    • Export Citation
  • 9

    Lawson McLean AC, Rosahl SK. Growth dynamics of intracranial tumors in patients with neurofibromatosis type 2. World Neurosurg. 2017;98:152161.

    • Search Google Scholar
    • Export Citation
  • 10

    Hashimoto N, Rabo CS, Okita Y, Slower growth of skull base meningiomas compared with non-skull base meningiomas based on volumetric and biological studies. J Neurosurg. 2012;116(3):574580.

    • Search Google Scholar
    • Export Citation
  • 11

    Lee EJ, Kim JH, Park ES, A novel weighted scoring system for estimating the risk of rapid growth in untreated intracranial meningiomas. J Neurosurg. 2017;127(5):971980.

    • Search Google Scholar
    • Export Citation
  • 12

    Evans DG, Huson SM, Donnai D, A clinical study of type 2 neurofibromatosis. Q J Med. 1992;84(304):603618.

  • 13

    Evans DGR. Neurofibromatosis type 2 (NF2): a clinical and molecular review. Orphanet J Rare Dis. 2009;4:16.

  • 14

    Ferner RE, Shaw A, Evans DG, Longitudinal evaluation of quality of life in 288 patients with neurofibromatosis 2. J Neurol. 2014;261(5):963969.

    • Search Google Scholar
    • Export Citation
  • 15

    Halliday D, Emmanouil B, Pretorius P, Genetic Severity Score predicts clinical phenotype in NF2. J Med Genet. 2017;54(10):657664.

  • 16

    Parry DM, Eldridge R, Kaiser-Kupfer MI, Neurofibromatosis 2 (NF2): clinical characteristics of 63 affected individuals and clinical evidence for heterogeneity. Am J Med Genet. 1994;52(4):450461.

    • Search Google Scholar
    • Export Citation
  • 17

    Brugada-Bellsolà F, Teixidor Rodríguez P, Rodríguez-Hernández A, Growth prediction in asymptomatic meningiomas: the utility of the AIMSS score. Acta Neurochir (Wien). 2019;161(11):22332240.

    • Search Google Scholar
    • Export Citation
  • 18

    Blakeley JO, Evans DG, Adler J, Consensus recommendations for current treatments and accelerating clinical trials for patients with neurofibromatosis type 2. Am J Med Genet A. 2012;158A(1):2441.

    • Search Google Scholar
    • Export Citation
  • 19

    Goutagny S, Kalamarides M. Meningiomas and neurofibromatosis. J Neurooncol. 2010;99(3):341347.

  • 20

    Perry A, Giannini C, Raghavan R, Aggressive phenotypic and genotypic features in pediatric and NF2-associated meningiomas: a clinicopathologic study of 53 cases. J Neuropathol Exp Neurol. 2001;60(10):9941003.

    • Search Google Scholar
    • Export Citation
  • 21

    Fountain DM, Soon WC, Matys T, Volumetric growth rates of meningioma and its correlation with histological diagnosis and clinical outcome: a systematic review. Acta Neurochir (Wien). 2017;159(3):435445.

    • Search Google Scholar
    • Export Citation
  • 22

    Wentworth S, Pinn M, Bourland JD, Clinical experience with radiation therapy in the management of neurofibromatosis-associated central nervous system tumors. Int J Radiat Oncol Biol Phys. 2009;73(1):208213.

    • Search Google Scholar
    • Export Citation
  • 23

    Liu A, Kuhn EN, Lucas JT Jr, Gamma Knife radiosurgery for meningiomas in patients with neurofibromatosis Type 2. J Neurosurg. 2015;122(3):536542.

    • Search Google Scholar
    • Export Citation
  • 24

    Birckhead B, Sio TT, Pollock BE, Gamma Knife radiosurgery for neurofibromatosis type 2-associated meningiomas: a 22-year patient series. J Neurooncol. 2016;130(3):553560.

    • Search Google Scholar
    • Export Citation
  • 25

    Nguyen T, Chung LK, Sheppard JP, Surgery versus stereotactic radiosurgery for the treatment of multiple meningiomas in neurofibromatosis type 2: illustrative case and systematic review. Neurosurg Rev. 2019;42(1):8596.

    • Search Google Scholar
    • Export Citation
  • 26

    Baser ME, Evans DG, Jackler RK, Neurofibromatosis 2, radiosurgery and malignant nervous system tumours. Br J Cancer. 2000;82(4):998.

  • 27

    Evans DGR, Birch JM, Ramsden RT, Malignant transformation and new primary tumours after therapeutic radiation for benign disease: substantial risks in certain tumour prone syndromes. J Med Genet. 2006;43(4):289294.

    • Search Google Scholar
    • Export Citation

Metrics

All Time Past Year Past 30 Days
Abstract Views 71 71 71
Full Text Views 21 21 21
PDF Downloads 22 22 22
EPUB Downloads 0 0 0